Concepts (252)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vena Cava Filters | 17 | 2020 | 97 | 6.230 |
Why?
|
| Device Removal | 18 | 2020 | 167 | 4.530 |
Why?
|
| Vena Cava, Inferior | 12 | 2022 | 145 | 4.140 |
Why?
|
| Pulmonary Embolism | 10 | 2020 | 228 | 2.360 |
Why?
|
| Prosthesis Implantation | 5 | 2020 | 126 | 2.260 |
Why?
|
| Carcinoma, Hepatocellular | 8 | 2024 | 390 | 2.080 |
Why?
|
| Liver Neoplasms | 9 | 2024 | 754 | 1.920 |
Why?
|
| Venous Thrombosis | 8 | 2022 | 250 | 1.680 |
Why?
|
| Embolization, Therapeutic | 10 | 2024 | 262 | 1.290 |
Why?
|
| Chemoembolization, Therapeutic | 2 | 2022 | 35 | 1.290 |
Why?
|
| Catheter Ablation | 2 | 2022 | 252 | 1.100 |
Why?
|
| Treatment Outcome | 31 | 2024 | 8203 | 1.030 |
Why?
|
| Radiography, Interventional | 9 | 2019 | 154 | 0.880 |
Why?
|
| Cholecystostomy | 1 | 2020 | 4 | 0.740 |
Why?
|
| Cholecystitis, Acute | 1 | 2020 | 8 | 0.740 |
Why?
|
| Surgical Instruments | 1 | 2020 | 57 | 0.700 |
Why?
|
| Foreign-Body Migration | 1 | 2020 | 39 | 0.700 |
Why?
|
| Phlebography | 7 | 2017 | 66 | 0.700 |
Why?
|
| Prosthesis Design | 8 | 2019 | 296 | 0.670 |
Why?
|
| Liver Transplantation | 7 | 2013 | 1177 | 0.660 |
Why?
|
| Renal Dialysis | 6 | 2007 | 335 | 0.660 |
Why?
|
| Aorta | 1 | 2020 | 288 | 0.640 |
Why?
|
| Retrospective Studies | 21 | 2024 | 9003 | 0.640 |
Why?
|
| Stents | 3 | 2013 | 395 | 0.600 |
Why?
|
| Hemorrhage | 1 | 2019 | 278 | 0.590 |
Why?
|
| Microspheres | 3 | 2024 | 108 | 0.560 |
Why?
|
| Yttrium Radioisotopes | 7 | 2024 | 58 | 0.560 |
Why?
|
| Diagnostic Imaging | 2 | 2019 | 479 | 0.540 |
Why?
|
| Jugular Veins | 2 | 2014 | 74 | 0.530 |
Why?
|
| Femoral Vein | 2 | 2014 | 39 | 0.530 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 2 | 2006 | 43 | 0.520 |
Why?
|
| Endovascular Procedures | 2 | 2022 | 270 | 0.510 |
Why?
|
| Middle Aged | 29 | 2024 | 25863 | 0.500 |
Why?
|
| Microwaves | 1 | 2014 | 36 | 0.490 |
Why?
|
| Vena Cava, Superior | 3 | 2014 | 60 | 0.490 |
Why?
|
| Vascular Diseases | 2 | 2014 | 118 | 0.490 |
Why?
|
| Cholangiocarcinoma | 3 | 2024 | 76 | 0.480 |
Why?
|
| Radiopharmaceuticals | 2 | 2024 | 193 | 0.480 |
Why?
|
| Tumor Burden | 2 | 2024 | 308 | 0.470 |
Why?
|
| Bile Duct Neoplasms | 3 | 2024 | 90 | 0.470 |
Why?
|
| Brachiocephalic Veins | 1 | 2014 | 34 | 0.470 |
Why?
|
| Catheters, Indwelling | 4 | 2013 | 113 | 0.470 |
Why?
|
| Humans | 54 | 2024 | 89063 | 0.460 |
Why?
|
| Catheterization, Central Venous | 3 | 2013 | 115 | 0.450 |
Why?
|
| Aged | 20 | 2024 | 19077 | 0.440 |
Why?
|
| Time Factors | 10 | 2024 | 5320 | 0.430 |
Why?
|
| Female | 32 | 2024 | 46011 | 0.400 |
Why?
|
| Aged, 80 and over | 11 | 2021 | 6777 | 0.390 |
Why?
|
| Iatrogenic Disease | 2 | 2022 | 70 | 0.380 |
Why?
|
| Embolic Protection Devices | 1 | 2011 | 9 | 0.380 |
Why?
|
| Male | 31 | 2024 | 42251 | 0.380 |
Why?
|
| Iliac Vein | 1 | 2011 | 30 | 0.380 |
Why?
|
| Thrombectomy | 4 | 2022 | 172 | 0.370 |
Why?
|
| Portal Vein | 2 | 2013 | 120 | 0.370 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2011 | 44 | 0.370 |
Why?
|
| Bariatric Surgery | 2 | 2011 | 195 | 0.370 |
Why?
|
| Hepatic Artery | 3 | 2021 | 84 | 0.360 |
Why?
|
| Hepatic Duct, Common | 1 | 2009 | 10 | 0.340 |
Why?
|
| Biliary Fistula | 1 | 2009 | 11 | 0.340 |
Why?
|
| Arteriovenous Shunt, Surgical | 2 | 2007 | 71 | 0.340 |
Why?
|
| Disease Progression | 1 | 2024 | 1488 | 0.340 |
Why?
|
| Angioplasty, Balloon | 2 | 2007 | 96 | 0.340 |
Why?
|
| Adult | 19 | 2024 | 26507 | 0.320 |
Why?
|
| Anticoagulants | 5 | 2020 | 426 | 0.320 |
Why?
|
| Liver Cirrhosis | 2 | 2009 | 254 | 0.320 |
Why?
|
| Venous Thromboembolism | 1 | 2011 | 159 | 0.310 |
Why?
|
| Obesity, Morbid | 1 | 2011 | 233 | 0.310 |
Why?
|
| Arm | 1 | 2007 | 97 | 0.290 |
Why?
|
| Chicago | 3 | 2019 | 1423 | 0.290 |
Why?
|
| Risk Factors | 5 | 2024 | 5466 | 0.280 |
Why?
|
| Aneurysm, False | 3 | 2013 | 54 | 0.260 |
Why?
|
| Ischemia | 1 | 2007 | 251 | 0.260 |
Why?
|
| Thrombolytic Therapy | 3 | 2020 | 232 | 0.260 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2007 | 226 | 0.250 |
Why?
|
| Postoperative Complications | 5 | 2013 | 2275 | 0.230 |
Why?
|
| Prosthesis Failure | 3 | 2014 | 116 | 0.230 |
Why?
|
| Follow-Up Studies | 5 | 2017 | 3657 | 0.210 |
Why?
|
| Hepatectomy | 1 | 2024 | 170 | 0.210 |
Why?
|
| Tomography, X-Ray Computed | 8 | 2021 | 2657 | 0.210 |
Why?
|
| Constriction, Pathologic | 5 | 2022 | 217 | 0.210 |
Why?
|
| Cholangiography | 2 | 2005 | 40 | 0.210 |
Why?
|
| Propensity Score | 1 | 2022 | 147 | 0.200 |
Why?
|
| Bile | 1 | 2001 | 57 | 0.190 |
Why?
|
| Fistula | 1 | 2021 | 42 | 0.190 |
Why?
|
| Tokyo | 1 | 2020 | 3 | 0.190 |
Why?
|
| Adolescent | 9 | 2021 | 9237 | 0.180 |
Why?
|
| Mechanical Thrombolysis | 1 | 2020 | 16 | 0.180 |
Why?
|
| Vascular Patency | 5 | 2022 | 126 | 0.170 |
Why?
|
| Brachytherapy | 1 | 2021 | 121 | 0.170 |
Why?
|
| Hypotension | 1 | 2020 | 71 | 0.170 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2019 | 38 | 0.170 |
Why?
|
| Catheterization | 3 | 2008 | 237 | 0.170 |
Why?
|
| Radiation Exposure | 1 | 2019 | 24 | 0.170 |
Why?
|
| Equipment Safety | 2 | 2011 | 33 | 0.170 |
Why?
|
| Mortality | 1 | 2020 | 149 | 0.160 |
Why?
|
| Renal Veins | 2 | 2017 | 28 | 0.160 |
Why?
|
| Radiation Dosage | 1 | 2019 | 225 | 0.160 |
Why?
|
| Anesthesia, General | 1 | 2019 | 118 | 0.160 |
Why?
|
| Bile Ducts, Intrahepatic | 3 | 2023 | 72 | 0.160 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2020 | 136 | 0.160 |
Why?
|
| Radiography | 4 | 2013 | 809 | 0.160 |
Why?
|
| Young Adult | 5 | 2021 | 6288 | 0.150 |
Why?
|
| Recurrence | 1 | 2020 | 1140 | 0.140 |
Why?
|
| Length of Stay | 1 | 2020 | 732 | 0.140 |
Why?
|
| Pipecolic Acids | 2 | 2006 | 14 | 0.140 |
Why?
|
| Chronic Disease | 1 | 2020 | 948 | 0.140 |
Why?
|
| Risk Assessment | 4 | 2013 | 2290 | 0.140 |
Why?
|
| Fluoroscopy | 1 | 2016 | 122 | 0.130 |
Why?
|
| Anastomosis, Surgical | 2 | 2009 | 273 | 0.130 |
Why?
|
| Graft Occlusion, Vascular | 2 | 2007 | 99 | 0.130 |
Why?
|
| Thrombin | 2 | 2013 | 61 | 0.130 |
Why?
|
| Hemostatics | 2 | 2013 | 57 | 0.130 |
Why?
|
| Angioplasty | 2 | 2013 | 70 | 0.120 |
Why?
|
| Computed Tomography Angiography | 1 | 2016 | 146 | 0.120 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 1837 | 0.120 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2006 | 237 | 0.110 |
Why?
|
| Sampling Studies | 1 | 2013 | 72 | 0.110 |
Why?
|
| Mesenteric Veins | 1 | 2013 | 33 | 0.110 |
Why?
|
| Abdominal Injuries | 1 | 2013 | 46 | 0.110 |
Why?
|
| Foreign Bodies | 1 | 2013 | 66 | 0.100 |
Why?
|
| Endoleak | 1 | 2012 | 41 | 0.100 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2013 | 111 | 0.100 |
Why?
|
| Contraindications | 1 | 2011 | 70 | 0.090 |
Why?
|
| Feasibility Studies | 2 | 2011 | 779 | 0.090 |
Why?
|
| Child, Preschool | 5 | 2006 | 3717 | 0.090 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2012 | 120 | 0.090 |
Why?
|
| Survival Rate | 1 | 2014 | 1889 | 0.090 |
Why?
|
| Renal Artery | 1 | 2010 | 52 | 0.090 |
Why?
|
| Plasma | 2 | 2007 | 51 | 0.090 |
Why?
|
| Equipment Design | 1 | 2011 | 415 | 0.090 |
Why?
|
| Portal System | 1 | 2009 | 13 | 0.090 |
Why?
|
| Balloon Occlusion | 1 | 2009 | 29 | 0.080 |
Why?
|
| Liver Failure | 1 | 2009 | 67 | 0.080 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2009 | 109 | 0.080 |
Why?
|
| Contrast Media | 3 | 2013 | 1090 | 0.080 |
Why?
|
| Alloys | 1 | 2007 | 10 | 0.080 |
Why?
|
| Axillary Vein | 1 | 2007 | 5 | 0.080 |
Why?
|
| Nephrectomy | 1 | 2010 | 293 | 0.080 |
Why?
|
| Brachial Artery | 1 | 2007 | 36 | 0.070 |
Why?
|
| Hemostasis | 1 | 2007 | 21 | 0.070 |
Why?
|
| Body Mass Index | 1 | 2011 | 771 | 0.070 |
Why?
|
| Liver Diseases | 1 | 2009 | 242 | 0.070 |
Why?
|
| Budd-Chiari Syndrome | 1 | 2006 | 9 | 0.070 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2007 | 45 | 0.070 |
Why?
|
| Blood Coagulation | 1 | 2007 | 92 | 0.070 |
Why?
|
| Thrombosis | 2 | 2006 | 302 | 0.070 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2006 | 34 | 0.070 |
Why?
|
| Dilatation | 1 | 2006 | 48 | 0.070 |
Why?
|
| Prosthesis-Related Infections | 1 | 2007 | 60 | 0.070 |
Why?
|
| Potassium | 5 | 1990 | 253 | 0.070 |
Why?
|
| Tuberculosis, Gastrointestinal | 1 | 2006 | 5 | 0.070 |
Why?
|
| Microarray Analysis | 1 | 2006 | 96 | 0.070 |
Why?
|
| Mesenteric Arteries | 1 | 2006 | 29 | 0.070 |
Why?
|
| Bacteremia | 1 | 2007 | 102 | 0.070 |
Why?
|
| Microfluidics | 1 | 2006 | 52 | 0.070 |
Why?
|
| Angiography | 2 | 2021 | 208 | 0.070 |
Why?
|
| Spasm | 1 | 2005 | 17 | 0.070 |
Why?
|
| Nitroglycerin | 1 | 2005 | 23 | 0.070 |
Why?
|
| Graft Survival | 1 | 2009 | 898 | 0.060 |
Why?
|
| Punctures | 1 | 2005 | 29 | 0.060 |
Why?
|
| Biliary Tract Diseases | 1 | 2005 | 36 | 0.060 |
Why?
|
| Vasodilator Agents | 1 | 2005 | 146 | 0.060 |
Why?
|
| Kidney Neoplasms | 1 | 2010 | 635 | 0.060 |
Why?
|
| Retreatment | 2 | 2021 | 108 | 0.060 |
Why?
|
| Hypertrophy | 1 | 2024 | 67 | 0.060 |
Why?
|
| Liver Regeneration | 1 | 2024 | 36 | 0.060 |
Why?
|
| Staphylococcal Infections | 1 | 2007 | 269 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 2411 | 0.050 |
Why?
|
| Research Design | 1 | 2007 | 597 | 0.050 |
Why?
|
| Necrosis | 1 | 2023 | 209 | 0.050 |
Why?
|
| Venous Pressure | 1 | 2002 | 11 | 0.050 |
Why?
|
| Leiomyoma | 1 | 2005 | 200 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2007 | 786 | 0.050 |
Why?
|
| Uterine Neoplasms | 1 | 2005 | 245 | 0.050 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2001 | 25 | 0.050 |
Why?
|
| Catheterization, Peripheral | 1 | 2001 | 60 | 0.050 |
Why?
|
| Age Factors | 1 | 2005 | 1867 | 0.040 |
Why?
|
| Drainage | 1 | 2001 | 162 | 0.040 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2002 | 242 | 0.040 |
Why?
|
| Erythrocyte Membrane | 2 | 1990 | 61 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2002 | 729 | 0.040 |
Why?
|
| Erythrocytes | 2 | 1989 | 254 | 0.040 |
Why?
|
| Infant | 3 | 2013 | 3147 | 0.040 |
Why?
|
| Arginine | 2 | 2006 | 138 | 0.030 |
Why?
|
| Chlorides | 3 | 1989 | 103 | 0.030 |
Why?
|
| Sulfonamides | 2 | 2006 | 317 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 2010 | 1591 | 0.030 |
Why?
|
| Angiography, Digital Subtraction | 2 | 2005 | 99 | 0.030 |
Why?
|
| Child | 4 | 2006 | 7149 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2013 | 125 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2013 | 287 | 0.030 |
Why?
|
| Sodium | 2 | 1990 | 331 | 0.030 |
Why?
|
| Erythrocytes, Abnormal | 1 | 1989 | 12 | 0.020 |
Why?
|
| Comorbidity | 1 | 2013 | 948 | 0.020 |
Why?
|
| Incidence | 1 | 2013 | 1592 | 0.020 |
Why?
|
| Ion Channels | 1 | 1990 | 246 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 2014 | 0.020 |
Why?
|
| Anemia, Sickle Cell | 1 | 1989 | 144 | 0.020 |
Why?
|
| Phospholipids | 1 | 2007 | 111 | 0.020 |
Why?
|
| Hemofiltration | 1 | 2006 | 11 | 0.020 |
Why?
|
| Duodenum | 1 | 2007 | 103 | 0.020 |
Why?
|
| Titrimetry | 1 | 2006 | 15 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2007 | 150 | 0.020 |
Why?
|
| Radiology, Interventional | 1 | 2006 | 69 | 0.020 |
Why?
|
| Life Tables | 1 | 2005 | 48 | 0.020 |
Why?
|
| Ointments | 1 | 2005 | 12 | 0.020 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2005 | 51 | 0.020 |
Why?
|
| Gastric Bypass | 1 | 2007 | 110 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2006 | 434 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 2752 | 0.020 |
Why?
|
| Administration, Cutaneous | 1 | 2005 | 60 | 0.020 |
Why?
|
| Femur | 1 | 2005 | 111 | 0.020 |
Why?
|
| Arteries | 1 | 2005 | 180 | 0.010 |
Why?
|
| Biological Transport | 3 | 1989 | 401 | 0.010 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2005 | 168 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2010 | 1363 | 0.010 |
Why?
|
| Kidney Failure, Chronic | 1 | 2006 | 413 | 0.010 |
Why?
|
| Reoperation | 1 | 2005 | 598 | 0.010 |
Why?
|
| Phlebotomy | 1 | 2001 | 21 | 0.010 |
Why?
|
| Collateral Circulation | 1 | 2001 | 35 | 0.010 |
Why?
|
| Veins | 1 | 2001 | 95 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2006 | 2476 | 0.010 |
Why?
|
| United States | 1 | 2013 | 6955 | 0.010 |
Why?
|
| 4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid | 2 | 1989 | 3 | 0.010 |
Why?
|
| Methazolamide | 2 | 1989 | 3 | 0.010 |
Why?
|
| 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid | 2 | 1989 | 17 | 0.010 |
Why?
|
| Sheep | 2 | 1990 | 250 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2001 | 711 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 1989 | 499 | 0.010 |
Why?
|
| Cell Membrane Permeability | 1 | 1990 | 120 | 0.010 |
Why?
|
| Cations | 1 | 1989 | 30 | 0.010 |
Why?
|
| Electric Conductivity | 1 | 1989 | 144 | 0.010 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1989 | 112 | 0.010 |
Why?
|
| Permeability | 1 | 1989 | 137 | 0.010 |
Why?
|
| Hemoglobin SC Disease | 1 | 1989 | 1 | 0.010 |
Why?
|
| Carbonyl Cyanide m-Chlorophenyl Hydrazone | 1 | 1989 | 4 | 0.010 |
Why?
|
| Water-Electrolyte Balance | 1 | 1989 | 67 | 0.010 |
Why?
|
| Dogs | 1 | 1990 | 704 | 0.010 |
Why?
|
| Bumetanide | 1 | 1988 | 4 | 0.010 |
Why?
|
| Electrophysiology | 1 | 1989 | 403 | 0.010 |
Why?
|
| Membrane Potentials | 1 | 1990 | 436 | 0.010 |
Why?
|
| Anions | 1 | 1988 | 31 | 0.000 |
Why?
|
| Ouabain | 1 | 1988 | 24 | 0.000 |
Why?
|
| Biological Transport, Active | 1 | 1988 | 102 | 0.000 |
Why?
|
| Osmolar Concentration | 1 | 1988 | 181 | 0.000 |
Why?
|
| Furosemide | 1 | 1988 | 34 | 0.000 |
Why?
|
| Hemolysis | 1 | 1988 | 64 | 0.000 |
Why?
|
| Rabbits | 1 | 1989 | 638 | 0.000 |
Why?
|
| In Vitro Techniques | 1 | 1989 | 996 | 0.000 |
Why?
|
| Kinetics | 1 | 1988 | 1528 | 0.000 |
Why?
|
| Calcium | 1 | 1989 | 1172 | 0.000 |
Why?
|
| Animals | 2 | 1990 | 27317 | 0.000 |
Why?
|